Deutsche Bank Raises PT on Gilead Sciences (GILD); Expect Approval of Quad on 8/27 Followed by Strong Launch
Tweet Send to a FriendGet Alerts GILD Hot Sheet
Price: $56.47 --0%
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 22 | New: 11
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 22 | New: 11
Trade GILD Now!
Deutsche Bank maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $68.00 (from $65.00).
Analyst, Robyn Karnauskas, said, "We believe approval is almost certain due to positive FDA panel in May & Quad already being added to US HIV treatment guidelines...Mgmt says Quad launch will be stronger than Complera, but weaker than Atripla. Atripla sold $206M in ‘06 & Complera $49M in ’11...We expect pricing at a ~19-30% premium to Complera since Quad is more convenient than both Isentress & boosted PI markets and less tox than Atripla...In EU, Atripla is first line therapy although it sold $1B in 2011. Pro-Viread data will readout Q412, which may extend Viread patent if better than Viread."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.57 yesterday, with a 52 week range of $34.45-$58.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Robyn Karnauskas, said, "We believe approval is almost certain due to positive FDA panel in May & Quad already being added to US HIV treatment guidelines...Mgmt says Quad launch will be stronger than Complera, but weaker than Atripla. Atripla sold $206M in ‘06 & Complera $49M in ’11...We expect pricing at a ~19-30% premium to Complera since Quad is more convenient than both Isentress & boosted PI markets and less tox than Atripla...In EU, Atripla is first line therapy although it sold $1B in 2011. Pro-Viread data will readout Q412, which may extend Viread patent if better than Viread."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.57 yesterday, with a 52 week range of $34.45-$58.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
- Actavis (ACT) Fairly Valued After Run-Up - Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDARelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
